Radiofrequency Ablation For Chronic Migraine – A Randomized Controlled Trial

Radiofrequency Ablation For Chronic Migraine – A Randomized Controlled Trial - RMig Trial

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2022/05/042401

Enrollment

Registered

2022-05-06

Start date

Unknown

Completion date

Unknown

Last updated

2024-11-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: O- Medical and Surgical

Interventions

Intervention1: Radiofrequency ablation: The trigger site will be confirmed using a preoperative local anesthetic (Bupivacaine block). Thereafter, under local anesthesia (Bupivacaine) with SOS midazola

Eligibility

Inclusion criteria

Inclusion criteria: 1. Patients with chronic or drug refractory migraine 2. Patients who had >50% relief with local anesthetic block (0.5% Bupivacaine).

Exclusion criteria

Exclusion criteria: Patient refusal

Design outcomes

Primary

Measure	Time frame
To study the pain outcomes of RF ablation for migraine using Visual analog score and migraine headache indexTimepoint: 7 days, 1 month, 3 months, 6 months, 12 months	—

Secondary

Measure	Time frame
To study the functional outcomes of RF ablation for migraine using Migraine disability assessment test (MIDAS score) and Pain self-efficacy questionnaire (PSEQ)Timepoint: 7 days, 1 month, 3 months, 6 months, 12 months	—

Countries

India

Contacts

Public ContactJitin Bajaj

Netaji Subhash Chandra Bose Medical College, Jabalpur

bajaj.jitin@gmail.com

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026